Saturday, 21 February 2015

Missing bits

Electronic filing is now the standard way to do most things at the European Patent Office, apart from the obvious exceptions where an appearance in person is required. The EPO's online filing software platform, although not perfect, is generally pretty good. Provided you can get around the extremely picky technical requirements for what documents it will accept, it is fairly straightforward for a reasonably IT-competent person to prepare and file an application, examination report response, opposition, appeal or whatever else takes your fancy. Secretarial support is often useful, and can save time in dealing with the mechanics of creating and uploading documents and entering details, but it is of course critically important to remember that it is the patent attorney who remains ultimately responsible for what is uploaded and sent using the software.

A key feature of the EPO's online filing software is the use of a smart card (like the one on the right). These are issued, free of charge, to attorneys and their support staff. Only attorneys are able to sign documents using the software, but support staff can use smart cards to send documents that have already been signed. The EPO have this to say about why they use smart cards and how secure they are:
Smart cards are credit card-sized plastic cards that contain a microprocessor and a small amount of memory.

The EPO decided very early on in the planning process for its online services that the certificates which would allow users to conduct secure transactions with us would be stored on smart cards. Unlike passwords, smart cards allow us to provide the more secure two-factor authentication, comprising something that is held (the card) and something that is known (the PIN.) Two-factor authentication means that PINs can be simpler and therefore easier to remember than with a password, since, without the card, the PIN is useless, and vice versa. Also, the simpler PINs are not susceptible to brute-force attacks because the smart card locks out after several unsuccessful attempts to enter the PIN.

In addition to being small and portable, smart cards afford a much higher level of secure storage for certificates than, say, if they are stored on a hard drive. They offer tamper-proof storage of the user's private keys and digital certificates, are highly resistant to unauthorised deletion or copying of the certificates and keys, and any attempt to tamper with them requires significant effort which would invariably result in physical damage to the cards themselves. Also, it is easier to spot the loss or theft of a card than of a certificate stored on a computer.
It helps here to know a little bit about how public-key cryptography works. When you want to send an electronic document securely to another person, but the transmission path is insecure (for example over the internet), the document needs to be encrypted somehow. If you and the recipient have a code that only you and they know, you can use this code to encrypt the document and the recipient can use the same code to decrypt the document at the other end. Someone obtaining the encrypted document along the way would only be able to get at the document if they either know or can work out the key. This is known as symmetric cryptography. The downside of this is that the key for encryption and decryption needs to be kept secret, as well as being shared by the sender and recipient. This is obviously difficult to achieve, particularly when the parties are far away from each other. A better way is to make the encryption and decryption asymmetric, where a different key is required to encrypt and decrypt. The sender can then encrypt the document using a public key, and the recipient can decrypt it with their private key. The encryption key can safely be made public, since knowledge of one cannot easily result in knowledge of the other (unless perhaps you know an easy way of factoring large numbers into primes; fame and fortune awaits if you can do it). The advantage of this is that anyone can find out a public key, and can encrypt and send documents to the recipient without needing to share anything with them beforehand.

The EPO's online filing software uses asymmetric cryptography, but in a different way. Instead of using a public key to encrypt an electronic document, the sender (i.e. the patent attorney) uses a private key, which is accessible via their smart card in combination with a secret PIN, to sign (i.e. encrypt) the documents to be sent to the EPO [this is not quite how it works, as explained in one of the helpful comments below, but the general principle is the same]. Since these documents can only be decrypted by the other (public) key, this provides an assurance that the documents were signed by the person authorised to do so. This is known as non-repudiation, and is of course an essential feature in ensuring that whoever signs is taking responsibility for what is being sent. Another feature inherent in this system is that the signed documents can only be sent in their entirety, and cannot be amended in any way once they have been signed. This allows another feature of the EPO's online filing software to work, which is that an electronic receipt is issued once a signed set of documents is successfully received by the EPO. This receipt always includes a "Message Digest", which is a string of hexadecimal codes that is uniquely derived from the content of what was transmitted, presumably the result of a hash function performed on the signed documents.

All this should be fairly simple for a patent attorney to understand, particularly if they deal with anything computer-related in their day to day work. Once the basic principles are understood, it should be clear that electronic filing, as well as providing a convenient way to transmit documents to the EPO, provides much greater assurance to the sender that what was sent has actually been received. Compared to the old way of doing things, where a set of paper documents would be signed off by the attorney and then be passed through several pairs of hands before arriving at the EPO, electronic filing provides much more assurance to the nervous attorney who might be worried about getting things done correctly.

All this is by way of introduction to a recent EPO Boards of appeal decision T 1101/14, which I noticed on the PatLit blog here. The case relates to EP application 08743225.8, which was refused by the examining division in December 2013. The applicant then appealed the decision, their attorney filing a notice of appeal the following month. The attorney then filed a statement of grounds of appeal, together with several sets of claims as main and auxiliary requests. Shortly afterwards, the EPO issued a formalities report, indicating that the grounds of appeal had not actually been filed. What had been sent was only a one page cover letter, and the statement of grounds with the supporting arguments had not been included. The attorney then requested re-establishment of rights, arguing that the missing grounds had been the result of "an isolated error of a suitable experienced and normally reliable secretary". The attorney had not noticed that the grounds were missing, but argued that "the two errors were uncharacteristic and isolated mistakes in an otherwise secure system". The board indicated that they had no doubts regarding the professional qualifications of the secretary, nor of the quality of supervision by the representative, but considered that "signing the wrong documents is incompatible with all due care unless special circumstances are invoked which could justify the representative's mistake in a particular case, thus following the cited reasons of T 1095/06" (point 6.5 of the reasons). In this case, there were no such special circumstances, and the request for re-establishment was refused.

Among the arguments submitted by the attorney was one that struck me as being quite odd. This was summarised in point 2.3 of the reasons, relating to why the attorney had not noticed the error when the filing receipt indicated only two pages in the letter of appeal and did not indicate the presence of a 12 page document. The board stated:
The representative has however argued that she does not - and is not required to - check the electronic acknowledgement of receipt, as this is a secretarial task. She explained that, according to the procedure for elec­tronic filing used in her office, the primary pur­pose of the acknowledgement of receipt is to confirm that the documents received at the EPO tally with the trans­mitted ones so that, in the case of a transmission problem, some or all of the documents can be sent again.
Given the explanation I have provided above of how the online filing software works, this seems to me to indicate such a basic lack of understanding that the error resulting in the missing grounds of appeal was almost bound to happen at some point. Contrary to the view expressed by the attorney, it would never be the case with online filing that only some of the documents would be sent. Instead, it can be either all or nothing. If a filing receipt is issued, this is a definite indication that what was signed was received by the EPO. Electronic filing does not work in the same way as operating a fax machine, where sometimes pages can be skipped so it is always essential to check that the correct number of pages has been transmitted.

So what lessons should be learned from this? The main one, to my mind, is that when using online filing it is of utmost importance that the attorney checks the documents that are going to be sent on screen, and not in the form of a printout. Many attorneys still prefer to check printed documents, but this cannot provide assurance, regardless of how reliable your secretary is, that what is being checked is the same as what has been uploaded. Another lesson, however, which shouldn't really need to be learned by any attorney, is that the patent attorney is the one that has to take ultimate responsibility for what is signed and sent to the EPO. Blaming secretaries is not usually going to work.

Friday, 13 February 2015


It is well known that while a drug is protected by a patent, its price will be higher than it would otherwise be. This is, of course, the reason for having a patent. Sometimes this price can be very high indeed, for example where a patented drug is very much more effective than anything else currently available, for which people will be prepared to pay a lot more. In a free market, the price of any patented drug would be determined simply by how much the patent holder could get away with charging. The optimum price for the patent holder will be the one that maximises profits, which will of course not necessarily be the maximum price they can get away with. The market in drugs, however, doesn't always work like that, and in some cases the market is, for various reasons, not free at all. Whereas in the US, pharmaceutical companies can charge pretty much whatever they like and see what the market can bear, in Europe the situation is much more complicated. In the UK, the NHS will strike a deal with pharmaceutical companies to get the best price they can, and there is an incentive for the patent holder not to charge too much because otherwise the patented drug will not be considered cost effective by NICE and will therefore not be generally prescribed.

It is obvious that there are many factors in play when a patent holder decides what to charge for their drug in each country they wish to sell it in. In some countries it might not be possible to even get a patent for the drug. A decision will then need to be made on whether to market the drug in that country at all, if the price that can be charged is not worth it. In other countries where a patent is possible, a patent holder may need to charge the same price throughout an entire region, in order to prevent parallel importation from becoming a drain on profits. This is the case in Europe, where different deals may be struck in different EU countries, resulting in different prices being charged. Sometimes the price being demanded is so high that complaints start to be raised.

A recent complaint about high pricing relates to the price Gilead are currently charging for their patented drug Sofusbuvir (trade name: Sovaldi or Virunon), a new drug for treating hepatitis C virus (HCV) infections. In the UK, a price of £35,000 for a typical 12 week treatment course has been quoted (see the Wikipedia link above). NICE have as yet not issued any guidance as to whether Sofusbuvir should be funded on the NHS, although a decision is expected this month (see here).

In France, the issue has been raised by the charity Médecins du Monde, which describes itself as "an international humanitarian organisation providing medical care to vulnerable populations affected by war, natural disasters, disease, famine, poverty or exclusion". It has recently, however, apparently extended its remit to cover objecting when high prices are charged for patented drugs. A press release of theirs, issued on 10 February, states:
Today, Doctors of the World - Médecins du Monde (MDM) has filed a European patent challenge against the Hepatitis C virus (HCV) drug, sofosbuvir. In recent months, Médecins du Monde and its partners have raised the alarm around the problems caused by the cost of new treatments against hepatitis C and of sofosbuvir in particular. The U.S.-based pharmaceutical company Gilead holds a monopoly for sofosbuvir and is marketing a 12-week course treatment at extremely high prices – 41 000 euros in France and 44 000 euros in the United Kingdom – thereby hindering access to the drug for People Living with HCV.
A patent challenge is a legal procedure by which the validity of a patent is questioned. While using sofosbuvir to treat hepatitis C represents an important step forward, the molecule itself is not sufficiently innovative to warrant a patent. If successful, it can encourage competition from generic versions of sofosbuvir, which can drive price reductions closer to the cost of production. According to experts, this cost for sofosbuvir may be as low as $101 USD for a 12-week course.
Since Gilead is prioritizing its private rights over human rights, imposing unconscionable prices for healthcare systems, Doctors of the World – MDM has decided to challenge Gilead. This is the first time in Europe that a medical non-governmental organisation (NGO) uses this procedure to improve patient access to drugs. MDM believes that the price of sofosbuvir is unjust in part because public funds were used to research and develop the drug.
We are defending universal access to healthcare: the struggle against health inequality involves safeguarding a healthcare system based on solidarity,” explains Dr Jean-François Corty, MdM’s French Programmes Director.“Even in a ‘rich’ country like France, with an annual medicines budget of 27 billion euros, it is difficult to meet this cost. We are seeing an arbitrary rationing approach that excludes patients from care, and this is unacceptable.”
According to the World Health Organisation (WHO), an estimated 130 to 150 million individuals are living with chronic hepatitis C. Within the European Union, it is estimated that between 7.3 and 8.8 million people are living with the virus. In France, 230, 000 people are reportedly chronic carriers of hepatitis C.
Patent challenges have already been used by civil society in India, Brazil, the United States and around the world to remove weak or unmerited patents for drugs and to make low-cost generic versions available,” explains Olivier Maguet,MdM board member delegate for hepatitis C. “This has led to a substantial reduction in the cost of treatments, enabling access to drugs of patients who would otherwise be deprived of life-saving medicines.” Doctors of the World - Médecins du Monde is taking up the fight to promote universal access to treatment against HCV in Europe and the rest of the world. MdM is also launching a public debate in France on the drug pricing mechanism and its impact on the healthcare system.
MdM do not actually indicate what patent is being opposed, but a copy of the opposition itself is linked to on this page, and states that the patent is EP2203462 (EP register here), which was granted on 21 May 2014. The deadline for filing oppositions does not end until 21 February 2015, so there is a chance that others may join in over the next few days, possibly making MdM's politically motivated contribution irrelevant. Given the very high value of the patent in question (which appears to be of the order of billions of whatever currency unit you favour), I think there is a very high probability of this happening. I suspect this one will run for a very long time, regardless of MdM's opposition.

UPDATE 20/2/15: As expected, more oppositions have been filed. Two further notices of opposition were filed yesterday: one by Dr. Holm Herbert Fleischer, a German doctor, and another by Ellis IP Limited (presumably acting as a straw man on behalf of an unidentified opponent). There seems to be a consistent theme among the three oppositions so far filed that there is an issue regarding the patent claiming the two stereoisomers of sofosbuvir, and in particular whether this is directly and unambiguously derivable from the application as filed (Article 123(2) EPC), whether the application discloses the invention sufficiently (Article 83 EPC) and whether the claimed invention has a valid right to priority (Article 87 EPC).

UPDATE 24/2/15: Four further oppositions have now been filed, making a grand total of seven now that the opposition deadline has passed. These extra four have been filed in the names of Actavis Group PTC ehf, STADA Arzneimittel AG, ZBM Patents and IPS. the latter two being apparently further strawmen oppositions. The six other oppositions, which were presumably made for sound commercial reasons rather than being politically motivated, make the MdM opposition seem a bit of a wasted effort.

UPDATE 5/3/15: The EP register now indicates a total of ten opponents, another three apparently getting in at the last minute. These are:

2. Fleischer, Holm Herbert
4. Pharmaceutical Works POLPHARMA
5. Generics [UK] Ltd (trading as Mylan)
6. Teva Pharmaceutical Industries Ltd
7. Intellectual Property Services (IPS)
8. STADA Arzneimittel AG
9. ZBM Patents - Zea, Barlocci & Markvardsen
10. Actavis Group PTC ehf

It looks like Gilead's representative (Sheila Wallace of Marks & Clerk) will be kept quite busy for some time.

In a related matter, a commenter has kindly pointed me to this article in the Grauniad. According to the author, who was lucky enough to have been successfully treated with sofusbuvir, socialism would be the answer to the problem of big pharma charging high prices for new drugs. He neglects, however, to explain how this would help in discovering these new drugs in the first place.